These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 6143633)

  • 1. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.
    Abernethy DR; Greenblatt DJ; Divoll M; Smith RB; Shader RI
    Clin Pharmacokinet; 1984; 9(2):177-83. PubMed ID: 6143633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics.
    Stoehr GP; Kroboth PD; Juhl RP; Wender DB; Phillips JP; Smith RB
    Clin Pharmacol Ther; 1984 Nov; 36(5):683-90. PubMed ID: 6149030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects.
    Pourbaix S; Desager JP; Hulhoven R; Smith RB; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):447-51. PubMed ID: 2864320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam.
    Abernethy DR; Greenblatt DJ; Divoll M; Moschitto LJ; Harmatz JS; Shader RI
    Psychopharmacology (Berl); 1983; 80(3):275-8. PubMed ID: 6137021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the newer benzodiazepines.
    Garzone PD; Kroboth PD
    Clin Pharmacokinet; 1989 Jun; 16(6):337-64. PubMed ID: 2567646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of propoxyphene with diazepam, alprazolam and lorazepam.
    Abernethy DR; Greenblatt DJ; Morse DS; Shader RI
    Br J Clin Pharmacol; 1985 Jan; 19(1):51-7. PubMed ID: 2858217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triazolam, an anomalous benzodiazepine receptor ligand: in vitro characterization of alprazolam and triazolam binding.
    Clow A; Glover V; Sandler M
    J Neurochem; 1985 Aug; 45(2):621-5. PubMed ID: 2861251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.
    Smith RB; Kroboth PD; Vanderlugt JT; Phillips JP; Juhl RP
    Psychopharmacology (Berl); 1984; 84(4):452-6. PubMed ID: 6152055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between single oral dose pharmacokinetics of alprazolam and triazolam.
    Otani K; Yasui N; Furukori H; Kaneko S; Tasaki H; Ohkubo T; Nagasaki T; Sugawara K; Hayashi K
    Int Clin Psychopharmacol; 1997 May; 12(3):153-7. PubMed ID: 9248872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of biological activity of alprazolam, triazolam and their metabolites.
    Sethy VH; Harris DW
    J Pharm Pharmacol; 1982 Feb; 34(2):115-6. PubMed ID: 6121870
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical pharmacokinetics of the newer benzodiazepines.
    Greenblatt DJ; Divoll M; Abernethy DR; Ochs HR; Shader RI
    Clin Pharmacokinet; 1983; 8(3):233-52. PubMed ID: 6133664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alprazolam kinetics in the elderly. Relation to antipyrine disposition.
    Greenblatt DJ; Divoll M; Abernethy DR; Moschitto LJ; Smith RB; Shader RI
    Arch Gen Psychiatry; 1983 Mar; 40(3):287-90. PubMed ID: 6131657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam.
    Miller LG; Greenblatt DJ; Barnhill JG; Deutsch SI; Shader RI; Paul SM
    J Neurochem; 1987 Nov; 49(5):1595-601. PubMed ID: 2889803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder.
    Ciraulo DA; Barnhill JG; Boxenbaum HG; Greenblatt DJ; Smith RB
    J Clin Pharmacol; 1986 Apr; 26(4):292-8. PubMed ID: 2871050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.
    Greenblatt DJ; Divoll M; Abernethy DR; Moschitto LJ; Smith RB; Shader RI
    Br J Clin Pharmacol; 1983 Mar; 15(3):303-9. PubMed ID: 6133545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
    Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
    Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age, gender, and obesity on midazolam kinetics.
    Greenblatt DJ; Abernethy DR; Locniskar A; Harmatz JS; Limjuco RA; Shader RI
    Anesthesiology; 1984 Jul; 61(1):27-35. PubMed ID: 6742481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men.
    Smith RB; Gwilt PR; Wright CE
    Clin Pharm; 1983; 2(2):139-43. PubMed ID: 6883942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
    Ghobadi C; Johnson TN; Aarabi M; Almond LM; Allabi AC; Rowland-Yeo K; Jamei M; Rostami-Hodjegan A
    Clin Pharmacokinet; 2011 Dec; 50(12):809-22. PubMed ID: 22087867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.